Monday, November 09, 2015 3:06:42 AM
SITC'15, Poster=B357(Bavi+PD-L1/Breast), Senior-Author: Duke's Dr. Herbert K. Lyerly. The Lead(publishing) author is Peregrine's Dr. Michael Gray, but interesting that Dr. Lyerly is listed as the last author (typically the Senior Author), along with 2 other Duke researchers listed as co-authors. Clearly Duke is working with Peregrine on pre-clinical bavituximab cancer I-O combination studies.
...As Johnny Carson would say, “I did not know that.”
2 other Duke scientists are listed as co-authors:
* Dr. Takuya Osada (MD/PhD – Duke Cancer Inst. - Hematology, Oncology, Clinical Immunology www.researchgate.net/profile/Takuya_Osada2 )
* Dr. Zachary Hartman (PhD) – Duke MC, Section of Applied Therapeutics http://surgery.duke.edu/faculty/details/0281172 ”My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies & dev. of vaccines to specific oncogenic targets.” ..
..
..
Here we have another dual company profile, for Peregrine scientist Michael Gray that is also still working for Quanticel (Celgene subsidiary)
-----------------------------
Tumors are comprised of different types of cancer cells at different stages of development.
Quanticel's proprietary technology enables isolation, characterization, and targeting of the individual tumor cells that are responsible for cancer recurrence.
..
..
Quanticel Pharmaceuticals has become a wholly owned subsidiary of Celgene Corporation. Visitors to this website will still be able to access relevant Quanticel content.
http://www.quanticel.com/
Michael Gray
scientist at Peregrine Pharmaceuticals
Orange County, California Area
Pharmaceuticals
Current
Peregrine Pharmaceuticals, Quanticel Pharmaceuticals
Previous
OSI
Education
MD Anderson Cancer Center
128
connections
Experience
scientist
Peregrine Pharmaceuticals
December 2014 – Present (1 year)
Scientist
Quanticel Pharmaceuticals
April 2013 – Present (2 years 8 months)
Senior scientist
OSI
2007 – 2010 (3 years)
..
..
..
https://www.linkedin.com/in/michael-gray-18447328
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
